High Tumor-Infiltrating Lymphocyte Count Is Associated with Distinct Gene Expression Profile and Longer Patient Survival in Advanced Ovarian Cancer.

Cancer-related immunity plays a significant role in the outcome of ovarian cancer, but the exact mechanisms are not fully explored. A retrospective, real-life observational study was conducted including 57 advanced ovarian cancer patients. Immunohistochemistry for CD4+, CD8+, and CD45+ was used for assessing tumor-infiltrating immune cells. Furthermore, an immune-related gene expression assay was performed on 12-10 samples from patients with less than and more than 1-year overall survival (OS), respectively. A higher number of CD4+ (p = 0.0028) and CD45+ (p = 0.0221) immune cells within the tumor microenvironment were associated with longer OS of patients. In a multivariate setting, higher CD4+ T cell infiltration predicted longer OS (p = 0.0392). Twenty-three differentially expressed genes-involved in antigen presentation, costimulatory signaling, matrix remodeling, metastasis formation, and myeloid cell activity-were found when comparing the prognostic groups. It was found that tumor-infiltrating immune cell counts are associated with peculiar gene expression patterns and bear prognostic information in ovarian cancer. SOX11 expression emerged and was validated as a predictive marker for OS.

[Cystic struma ovarii, a rare form of ovarian tumor--case report, and review of the literature]. / Cysticus struma ovarii, egy ritka ováriumtumor - esetismertetés és irodalmi áttekintés.

Struma ovarii represents less than 3% of ovarian teratomas. It can be associated with thyroid biology abnormalities, and in exceptionally rare cases it can be malignant. The authors report a case of a 31-year-old woman who underwent resection of a left ovarian cyst, presenting with the clinical features of an ovarian cancer (large pelvic mass, ascites and elevated CA-125 serum levels). The pathologic diagnosis was benign struma ovarii. The postoperative thyroid function remained normal.